Surgical Science Sweden AB (publ)
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator … Read more
Surgical Science Sweden AB (publ) (SUSRF) - Net Assets
Latest net assets as of September 2025: $4.30 Billion USD
Based on the latest financial reports, Surgical Science Sweden AB (publ) (SUSRF) has net assets worth $4.30 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.70 Billion) and total liabilities ($403.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.30 Billion |
| % of Total Assets | 91.42% |
| Annual Growth Rate | 62.47% |
| 5-Year Change | 1030.7% |
| 10-Year Change | 24535.91% |
| Growth Volatility | 243.15 |
Surgical Science Sweden AB (publ) - Net Assets Trend (2014–2024)
This chart illustrates how Surgical Science Sweden AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Surgical Science Sweden AB (publ) (2014–2024)
The table below shows the annual net assets of Surgical Science Sweden AB (publ) from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.83 Billion | +11.13% |
| 2023-12-31 | $4.35 Billion | +2.57% |
| 2022-12-31 | $4.24 Billion | +18.17% |
| 2021-12-31 | $3.59 Billion | +739.50% |
| 2020-12-31 | $427.05 Million | +6.32% |
| 2019-12-31 | $401.68 Million | +406.00% |
| 2018-12-31 | $79.38 Million | -7.18% |
| 2017-12-31 | $85.52 Million | +281.79% |
| 2016-12-31 | $22.40 Million | +14.29% |
| 2015-12-31 | $19.60 Million | -47.96% |
| 2014-12-31 | $37.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Surgical Science Sweden AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 66245585600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $639.41 Million | 13.24% |
| Common Stock | $2.55 Million | 0.05% |
| Other Components | $4.19 Billion | 86.71% |
| Total Equity | $4.83 Billion | 100.00% |
Surgical Science Sweden AB (publ) Competitors by Market Cap
The table below lists competitors of Surgical Science Sweden AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HALOSOURCE REG S
F:48H
|
$437.97 Million |
|
China Zhonghua Geotechnical Engineering Co Ltd
SHE:002542
|
$438.00 Million |
|
Pharmicell
KO:005690
|
$438.14 Million |
|
Companhia de Saneamento do Paraná - SANEPAR
SA:SAPR3
|
$438.22 Million |
|
ASP Isotopes Inc. Common Stock
NASDAQ:ASPI
|
$437.78 Million |
|
Huayi Compressor Co Ltd
SHE:000404
|
$437.73 Million |
|
Beijing Bewinner Communications Co Ltd
SHE:002148
|
$437.69 Million |
|
Cachet Pharmaceutical Co Ltd
SHE:002462
|
$437.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Surgical Science Sweden AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,345,212,000 to 4,828,638,000, a change of 483,426,000 (11.1%).
- Net income of 131,646,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 436,777,000.
- Other factors increased equity by 788,557,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $131.65 Million | +2.73% |
| Other Comprehensive Income | $-436.78 Million | -9.05% |
| Other Changes | $788.56 Million | +16.33% |
| Total Change | $- | 11.13% |
Book Value vs Market Value Analysis
This analysis compares Surgical Science Sweden AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.12x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 8.79x to 0.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $1.31 | $11.52 | x |
| 2015-12-31 | $0.81 | $11.52 | x |
| 2016-12-31 | $1.56 | $11.52 | x |
| 2017-12-31 | $4.36 | $11.52 | x |
| 2018-12-31 | $3.22 | $11.52 | x |
| 2019-12-31 | $13.83 | $11.52 | x |
| 2020-12-31 | $12.42 | $11.52 | x |
| 2021-12-31 | $84.02 | $11.52 | x |
| 2022-12-31 | $83.21 | $11.52 | x |
| 2023-12-31 | $85.30 | $11.52 | x |
| 2024-12-31 | $94.63 | $11.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Surgical Science Sweden AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.89%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.13x
- Recent ROE (2.73%) is above the historical average (1.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -16.18% | -7.39% | 0.83x | 2.63x | $-4.91 Million |
| 2015 | 8.16% | 3.47% | 0.84x | 2.79x | $-360.00K |
| 2016 | 14.73% | 6.37% | 0.81x | 2.84x | $1.06 Million |
| 2017 | -2.64% | -3.89% | 0.59x | 1.16x | $-10.81 Million |
| 2018 | -5.69% | -6.88% | 0.66x | 1.26x | $-12.46 Million |
| 2019 | 3.14% | 12.41% | 0.22x | 1.14x | $-27.57 Million |
| 2020 | 3.65% | 14.89% | 0.22x | 1.11x | $-27.10 Million |
| 2021 | 2.41% | 23.52% | 0.09x | 1.11x | $-272.26 Million |
| 2022 | 4.44% | 23.42% | 0.17x | 1.10x | $-235.67 Million |
| 2023 | 5.38% | 26.50% | 0.19x | 1.08x | $-200.55 Million |
| 2024 | 2.73% | 14.89% | 0.16x | 1.13x | $-351.22 Million |
Industry Comparison
This section compares Surgical Science Sweden AB (publ)'s net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $79,108,599
- Average return on equity (ROE) among peers: -247.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Surgical Science Sweden AB (publ) (SUSRF) | $4.30 Billion | -16.18% | 0.09x | $437.81 Million |
| Accolade, Inc. (ACCD) | $473.79 Million | -97.02% | 0.91x | $448.32 Million |
| Achiko AG (ACHKF) | $-4.58 Million | 0.00% | 0.00x | $314.42K |
| Ascom Holding AG (ACMLF) | $78.70 Million | 22.11% | 1.51x | $152.13 Million |
| Accelera Innovations Inc (ACNV) | $-462.52K | 0.00% | 0.00x | $5.72K |
| Aclarion Inc (ACON) | $-7.08 Million | 0.00% | 0.00x | $1.89 Million |
| Alternate Health Corp (AHGIF) | $1.07 Million | -2231.82% | 7.94x | $6.50K |
| AI/ML Innovations Inc (AIMLF) | $2.09 Million | -130.52% | 0.72x | $6.84 Million |
| NetraMark Holdings Inc. (AINMF) | $-198.56K | 0.00% | 0.00x | $70.13 Million |
| AMJ Global Technology (AMJT) | $-21.78K | 0.00% | 0.00x | $10.99 Million |
| American Well Corp (AMWL) | $247.79 Million | -38.62% | 0.31x | $78.62 Million |